The price of Aldeyra Therapeutics Inc (NASDAQ:ALDX) shares last traded on Wall Street fell -17.72% to $2.09.
Based on available information, 7 analysts follow Aldeyra Therapeutics Inc (NASDAQ:ALDX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $15.00 and a low of $7.00, we find $10.50. Given the previous closing price of $2.54, this indicates a potential upside of 313.39 percent. ALDX stock price is now -60.75% away from the 50-day moving average and -72.67% away from the 200-day moving average. The market capitalization of the company currently stands at $122.47M.
Among analysts, 1 rate the stock a hold while 6 rate it a buy. Brokers who have rated the stock have averaged $10.33 as their price target over the next twelve months.
In other news, PERCEPTIVE ADVISORS LLC, 10% Owner sold 306,499 shares of the company’s stock on Oct 18. The stock was sold for $533,308 at an average price of $1.74. Upon completion of the transaction, the 10% Owner now directly owns 8,593,586 shares in the company, valued at $17.96 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 16, 10% Owner PERCEPTIVE ADVISORS LLC sold 2,450,000 shares of the business’s stock. A total of $3,920,000 was realized by selling the stock at an average price of $1.60. This leaves the insider owning 8,900,085 shares of the company worth $18.6 million. Insiders disposed of 73,807 shares of company stock worth roughly $0.15 million over the past 1 year. A total of 3.93% of the company’s stock is owned by insiders.
A candlestick chart of Aldeyra Therapeutics Inc (NASDAQ: ALDX) showed a price of $2.5000 on Thursday morning. During the past 12 months, Aldeyra Therapeutics Inc has had a low of $1.42 and a high of $11.97. As of last week, the company has a debt-to-equity ratio of 0.12, a current ratio of 9.79, and a quick ratio of 9.79. The fifty day moving average price for ALDX is $5.2188 and a two-hundred day moving average price translates $7.6276 for the stock.
The latest earnings results from Aldeyra Therapeutics Inc (NASDAQ: ALDX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.15, beating analysts’ expectations of -$0.31 by 0.16. This compares to -$0.31 EPS in the same period last year. The company reported revenue of $10.34 million for the quarter, compared to $17.71 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -41.61 percent.
Aldeyra Therapeutics Inc(ALDX) Company Profile
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
